• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-27

  The study identifies CD44 as a metabolic dependency in IDH-mutant leukemia: it shifts glucose metabolism to sustain NADPH, which mutant IDH uses to produce the oncometabolite R-2HG. The findings suggest that combining IDH inhibition with CD44 blockade may provide a way to deepen leukemia-cell elimination, while requiring further validation in clinically relevant models.

• GM 6001 (Galardin): Interpreting MMP Perturbations

  2026-09-26

  GM 6001 (Galardin) is a broad-spectrum MMP inhibitor for probing how extracellular proteolysis shapes tissue remodeling and cell signaling. This article explains how to interpret its effects alongside—not as a substitute for—research on lysosomal membrane injury and cancer-cell death.

• Fucoidan Lowers Caveolin-1 in MCF-7 Breast Cancer Cells

  2026-09-25

  A 2026 in vitro study reports that fucoidan reduces MCF-7 cell viability, colony formation, migration, and caveolin-1 expression, with tamoxifen included as a comparator. The findings suggest a candidate link between fucoidan exposure and a cancer-associated membrane protein, but do not establish that caveolin-1 reduction causes the observed effects or predict efficacy in vivo.

• BicD and MAP7 Activate Drosophila Kinesin-1

  2026-09-25

  The study finds that BicD and MAP7 promote Drosophila kinesin-1 activity through distinct, complementary mechanisms: BicD relieves motor autoinhibition, while full-length MAP7 increases motor engagement with microtubules. Their combination produces the strongest activation in the reconstituted assays, while kinesin light chain reduces kinesin binding to BicD.

• Pifithrin-α: From p53 Mechanism to Translation

  2026-09-24

  A translational perspective on using Pifithrin-α to test p53-driven ferroptosis, interpret neurotoxicity findings, and strengthen causal experimental design.

• α-Bungarotoxin as a Causal Probe of α7 Signaling

  2026-09-24

  Explore how α-Bungarotoxin can test α7 nicotinic receptor involvement—not merely block cholinergic signaling—in neural and placental models. We connect receptor pharmacology to a preeclampsia-model study and outline practical controls, interpretation limits, and product-handling considerations.

• 2-NBDG Protocol for Cellular Glucose Uptake

  2026-09-23

  2-NBDG provides a fluorescent readout for comparing cellular glucose uptake across cell conditions using flow cytometry, microscopy, or microplate assays. It is a research tracer—not a direct measure of glucose flux or a diagnostic reagent—and should not be used for medical or diagnostic purposes.

• AG-120: Rewiring the IDH1 AML Research Strategy

  2026-09-23

  AG-120 (Ivosidenib) offers translational researchers a mechanistically grounded way to study mutant IDH1 biology, 2-hydroxyglutarate reduction, differentiation, and resistance. This thought-leadership perspective connects product-enabled experimentation with emerging evidence that CD44-driven metabolic rewiring sustains IDH-mutant leukemia.

• WecA Purification and Kinetic Analysis in Tuberculosis

  2026-09-22

  The reference study establishes a workable expression, purification, and activity-analysis strategy for Mycobacterium tuberculosis WecA, an 11-transmembrane-domain enzyme involved in mycobacterial cell-wall assembly. Its use of regulated expression in E. coli Lemo21(DE3), affinity purification, mass-spectrometric identification, and UMP-based kinetics provides a practical platform for studying WecA inhibition, including competitive inhibition by tunicamycin.

• Camostat Mesilate: Protease Assay Workflows

  2026-09-22

  Camostat Mesilate supports pathway-resolved studies of ENaC regulation, plasmin–TGF-β signaling, and hepatic fibrosis. This guide translates its biochemical profile into practical assay workflows while distinguishing protease inhibition from structure-guided blockade of viral protein–protein interactions.

• IGF2BP1–THBS1–TLR4 Axis in Pulmonary Fibrosis

  2026-09-21

  The 2025 reference study identifies an m6A-dependent IGF2BP1–THBS1–TLR4 axis that links macrophage glycolytic reprogramming with a profibrotic phenotype in pulmonary fibrosis. Its knockdown-and-rescue design provides mechanistic evidence that THBS1 mRNA stability, M2-like polarization, and glycolytic activity are interconnected, while also highlighting important limits for translation beyond the bleomycin model.

• Making Low-Abundance RNA Visible with Cy3 TSA

  2026-09-21

  A translational perspective on using tyramide signal amplification to spatially validate Lnc21q22.11 biology, strengthen gastric cancer research, and improve detection of low-abundance RNA and protein targets.

• Sulfo-Cy3 NHS Ester for Vascular Assays

  2026-09-20

  Sulfo-Cy3 NHS Ester combines water-compatible amine labeling with strong red fluorescence, making it useful for tracking proteins, endothelial interactions, and HDL-related uptake assays. This workflow translates the AIBP–LRP2–HDL findings into practical fluorescence experiments while addressing labeling ratio, hydrolysis, background, and cell-imaging challenges.

• CGP 55845 hydrochloride in GABAB Assays

  2026-09-19

  Use CGP 55845 hydrochloride to separate presynaptic GABAB signaling from astrocytic GAT-3 mechanisms in dentate gyrus experiments. This practical guide covers concentration planning, electrophysiology, calcium imaging, controls, and troubleshooting for reproducible in vitro neurotransmission assays.

• Golgi-Tracker Green: Live-Cell Imaging Workflow

  2026-09-18

  Build a reproducible live-cell Golgi imaging workflow for organelle morphology, lipid trafficking, and sphingolipid metabolism analysis. This guide also shows how to interpret Golgi fragmentation in oncology experiments without confusing a structural assay with a therapeutic mechanism.

8578 records 1/572 page Next 12345 下5页 Last page